About Schroedinger
                            Schrödinger is a healthcare-based software company that develops molecular design software for biotech and materials research.                        
                                                    
                                    Headquarters
                                    Schroedinger, New York
                                
                                                                                                
                                    Founded
                                    1990-08-16
                                
                                                                
                                                                
                                    Industry
                                    Biotechnology, Enterprise Software, Pharmaceutical, Software
                                
                                                                                                
                                    Last Funding Type
                                    Grant
                                
                                                                                                    
                                        Valuation
                                        0.8
                                    
                                                                                                
                                                                        Total Funding
                                    $577.22 million dollars
                                
                                                                                                
                                    IPO Status
                                    Public
                                
                                                            Financial
                                Schrödinger is advancing in molecular design software, focusing on predicting active compounds and their interactions with biomolecular targets. Their research includes methods for predicting docked positions of ligands in biomolecules, accounting for induced fit effects, and calculating free energy differences between states. These innovations aim to enhance the accuracy of molecular simulations and drug discovery processes, aligning with Schrödinger's expertise in biotech and materials research.
                            
                            
                                    Funding Rounds
                                    10
                                
                                                                                                
                                    Number of Lead Investors
                                    5
                                
                                                                                                
                                                                        Total Funding Amount 
                                    $577.22 million dollars
                                
                                                                                                
                                    Number of Investors
                                    16